---
title: "Weekly Recap | Bristol Myers Squibb this week, a quiet, range-bound stretch"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300846584.md"
description: "Bristol Myers Squibb (BMY) had no major catalyst this week, trading in a narrow range around $60-61. In-week news coverage was incomplete, so the day-to-day move cannot be fully described; the latest quote shows the stock at $61.15, easing to $61.02 in after-hours trading. The S&P 500 fell 0.27%, and BMY’s relative performance to the benchmark could not be calculated. Volume remained subdued, pointing to a range-bound week."
datetime: "2026-10-03T06:25:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300846584.md)
  - [en](https://longbridge.com/en/news/300846584.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300846584.md)
generator: "portal-rs"
---

# Weekly Recap | Bristol Myers Squibb this week, a quiet, range-bound stretch

## The Week

Bristol Myers Squibb (BMY) had no major catalyst this week, trading in a narrow range around $60-61. In-week news coverage was incomplete, so the day-to-day move cannot be fully described; the latest quote shows the stock at $61.15, easing to $61.02 in after-hours trading. The S&P 500 fell 0.27%, and BMY’s relative performance to the benchmark could not be calculated. Volume remained subdued, pointing to a range-bound week.

## Analyst Ratings

A total of 29 brokers cover the stock: 7 rate it buy, 3 overweight, 17 hold, 0 underweight, 1 sell, and 1 no opinion. The consensus rating is buy, with a consensus target of $66.71, about 9.09% above the current price. The target range spans $40 to $82, showing wide divergence. BMY ranks second in the pharmaceutical industry by rating, placing it near the top of the sector.

## The Week Ahead

Macro data is dense next week: US ISM non-manufacturing PMI and S&P Global services PMI final on 5 October, international trade balance on 6 October, and EIA weekly crude oil inventories on 7 October. No BMY-specific earnings are due next week; the Q3 report is scheduled for 29 October before the market opens. The macro calendar will likely set the tone for the healthcare sector in the near term.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

- [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md)
- [Bristol Myers Squibb secures expanded US approval for Camzyos](https://longbridge.com/en/news/300671144.md)
- [Bristol Myers Squibb (BMY) Doubles MRD‑Negative CR to 41.1% in Phase 3 EXCALIBER-RRMM](https://longbridge.com/en/news/300139432.md)
- [Bristol Myers Squibb wins FDA accelerated approval for ZENBEXUS combo in multiple myeloma](https://longbridge.com/en/news/300139167.md)
- [ROI-Oil's new problem isn't supply. It's logistics: Bousso](https://longbridge.com/en/news/300903866.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**